This would suggest that targeting these parameters would be a rational first step in the pre-operative optimisation in these patients.
Since vorinostat already has approval status, this would be a rational first choice of HDAC inhibitor, as several cancer centres with currently open trials have already realised.
This FDC is a rational second-line therapy given the complementary mechanisms of action of the components.
Then T : A → B is said to be a rational proximal contraction of the second kind if there exist nonnegative real numbers α, β, γ, δ with α + β + 2 γ + 2 δ < 1 such that the conditions d ( u 1, T x 1 ) = d ( A, B ) and d ( u 2, T x 2 ) = d ( A, B ). imply that (2).
In VerStrat Good group of NSCLC patients with wild-type or unknown status EGFR, the OS was not different between the patients treated with chemotherapy and those treated with erlotinib (10.9 versus 11.0 months; HR, 1.06; 95% CI, 0.77 1.46; P = 0.714), suggesting that EGFR-TKIs could be a rational choice for this subpopulation in second-line setting.
Don't be a rational idiot.
The addition of repaglinide to metformin therapy is a rational choice for second-line therapy as the two components have complementary mechanisms of action.
T is a rational proximal contraction of the first and second kinds; T ( A 0 ) ⊆ B 0. Then there exists a unique x ∈ B est ( T ).
Theorem 3.3 Let ( X, d ) be a complete metric space and A and ℬ be two nonempty, closed subsets of X. Assume that A 0 and B 0 are nonempty and T : A → B is a nonself-mapping such that: (a) T is a rational proximal contraction of the first and second kinds; (b) T ( A 0 ) ⊆ B 0. .
It is easy to show that T is a rational proximal contraction of the first and second kinds and T ( A 0 ) ⊆ B 0. Then all the hypotheses of the Theorem 3.3 are satisfied and d ( 1, T ( 1 ) ) = d ( A, B ). Clearly, the Theorem 3.2 is not applicable in this case.
